ETV1 and pachyonychia congenita: YK-4-279 treatment led to decreased ERG- and ETV1-dependent transcriptional activity, leading to reduced cell motility and invasion of PC cells, and reduced primary tumor growth and metastasis in PC xenografts models [19, 20].